Dr. Melanie Rolli joins PIQUR as new Chief Medical Officer
PIQUR Therapeutics AG, a Swiss clinical-stage pharmaceutical company, announced today that it has strengthened its management team with the appointment of Dr. Melanie Rolli as Chief Medical Officer.
“We are very pleased to welcome Melanie Rolli to PIQUR as our Chief Medical Officer,” said Vladimir Cmiljanovic, CEO of PIQUR Therapeutics. “Melanie’s broad research and drug development expertise and proven leadership skills will be instrumental to the future success of PIQUR.”
Melanie Rolli brings more than a decade of industry experience and senior responsibilities in global development, medical affairs and patient safety. She joins PIQUR from Novartis Pharma, where she held various positions with increasing responsibilities over the last 14 years, most recently as Global Head Medical Safety. Prior to joining Novartis, she worked as a medical doctor at the University Hospital in Mannheim and as a basic researcher in academic settings in Germany and at the Scripps Research Institute, USA.
PIQUR’s management team now consists of the following members:
- Vladimir Cmiljanovic, Chief Executive Officer
- Dr Melanie Rolli, Chief Medical Officer
- Doriano Fabbro, Chief Scientific Officer
- Hervé Girsault, Chief Business Officer
“I am excited to join the talented and passionate team at PIQUR at this stage, and I look forward to helping the team advance the development of new and innovative cancer therapies for patients in need,” said Melanie Rolli.
Download a PDF version of the press release here (English).